加载中
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
收盘时
US$16.09
−US$0.37 · -2.25%
盘后
US$16.09
US$0.00 · 0.00%
10月13日 16:40 ET
盘中时间采用ET。市场数据可能有所延迟。
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
日内区间
当前US$16.09
52周区间
当前US$16.09
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
36
偏贵
情绪
58
多空交织
风险
46
风险偏高
动量
67
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
日内区间
当前US$16.09
52周区间
当前US$16.09
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1.53亿 USD | 7900.4万 USD | 6488.4万 USD | 3043.3万 USD | 643.4万 USD |
| 销售、一般及管理费用 | 2418.3万 USD | 1530.4万 USD | 970.6万 USD | 647.3万 USD | 226.2万 USD |
| 营业费用 | 1.78亿 USD | 9430.8万 USD | 7459万 USD | 3690.6万 USD | 869.6万 USD |
| 利息收入 | 1122.6万 USD | 1382万 USD | 525.7万 USD | — | — |
| 折旧和摊销 | — | — | — | 3690.6万 USD | — |
| 营业利润 | −1.78亿 USD | −9430.8万 USD | −7459万 USD | −3690.6万 USD | −869.6万 USD |
| 净利润 | −1.66亿 USD | −8048.8万 USD | −6933.3万 USD | −3690.6万 USD | −5160.6万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$22.00
上涨空间 36.73%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4022.99万0.00%2.3万亿 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM1598.24万0.02%787.4亿 USD0.19%US$276.7-0.43%
State Street SPDR S&P Biotech ETFXBI1576.92万0.15%103.03亿 USD0.35%US$146.8-3.04%
Vanguard Extended Market ETFVXF1207.01万0.01%954亿 USD0.05%US$232.54-0.42%
Vanguard Russell 2000 ETFVTWO654.45万0.04%180亿 USD0.06%US$111.77-0.45%
iShares Russell 2000 Growth ETFIWO573.33万0.04%139.17亿 USD0.24%US$351.1-0.74%
iShares Biotechnology ETFIBB444.49万0.04%108.2亿 USD0.44%US$200.02-2.08%
Schwab U.S. Small-Cap ETFSCHA362万0.02%217.13亿 USD0.03%US$32.56-0.31%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
